Subsidiary (BVI) Clitina International Limited cash capital injection approved by BOD of CHLITINA HOLDING LIMITED
· Issued by Chlitina Holding Ltd.
Close
Today's Information
Provided by: CHLITINA HOLDING LIMITED
SEQ_NO
6
Date of announcement
2022/03/10
Time of announcement
20:42:22
Subject
Subsidiary (BVI) Clitina International Limited
cash capital injection approved by BOD of
CHLITINA HOLDING LIMITED
Date of events
2022/03/10
To which item it meets
paragraph 11
Statement
1.Date of the board of directors resolution:2022/03/10
2.Source of capital increase funds:capital increase by cash
3.Whether to adopt shelf registration (Yes, please state issuance period/No):
No.
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):USD4,000,000
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:NA
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:NA
7.Par value per share:USD1
8.Issue price:issued by par value per share
9.Number of shares subscribed for by or allocated to employees:None.
10.Number of shares publicly sold:NA
11.Ratio of shares subscribed by or allotted as stock dividends to existing
shareholders:NA
12.Handling method for fractional shares and shares unsubscripted for by
the deadline:NA
13.Rights and obligations of these newly issued shares:
The rights and obligations of the newly issued common shares are
the same as the existing common shares.
14.Utilization of the funds from the capital increase:
Invest in K&S Biomedical Ltd..
15.Any other matters that need to be specified:
(1)The capital injection flow is as follows: (BVI) Chlitina Holding Limited
→ (BVI) Chlitina Group Limited → (BVI) Chlitina International Limited.
The capital increase amount does not reach the threshold set by the TWSE
for public disclosure and therefore will not be announced.
(2)The chairman is authorized by the BoD to handle relevant matters such as
the date of the capital injection.
(3)This case is to authorize the chairman to reinvest in
"K&S Biomedical Ltd." in batches within the quota of NT$100,000,000,
depending on the operational situation, and implement the development
plan of the new channel in Taiwan.
(4)(BVI) Chlitina Group Limited and (BVI) Chlitina International Limited
are all 100%-owned by parent company.
